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Abstract. Background/Aim: Staphylococcus aureus infection
associated with orthopedic implants cannot always be
controlled. We used a knee prosthesis model with implant-
related osteomyelitis in rats to explore induction of an
effective immune response with active and passive
immunization. Materials and Methods: Fifty-two Sprague-
Dawley rats were divided into active (N=28) and passive
immunization groups (N=24). A bacterial inoculum of 103 S.
aureus MN8 was injected into the tibia and the femur marrow
before insertion of a non-constrained knee prosthesis in each
rat. The active-immunization group received a synthetic
oligosaccharide of polysaccharide poly-N-acetylglucosamine
(PNAG), 9G1cNH2 and the passive-immunization group
received immunization with immunoglobulin from rabbits
infected with S. aureus. Results/Conclusion: Active
immunization against PNAG significantly reduced the
consequences of osteomyelitis infection from PNAG-
producing intercellular adhesion (ica+) but not ica− S.
aureus. Passive immunization resulted in better clinical
assessments in animals challenged with either ica+ or ica−
S. aureus, suggesting a lack of specificity in this antiserum.
Infections associated with indwelling orthopedic devices can be
difficult to cure without removing the device, and therefore
expensive to manage (1). Although common infection-control
measures, such as laminar air flow in operating theatres and
administration of systemic antimicrobial prophylaxis, are
beneficial, they have not completely eliminated orthopedic
implant-related infections (2). In recent decades, there has been
a dramatic increase in Staphylococcus aureus infections,
particularly of those expressing resistance to multiple antibiotics,
throughout the community (3). S. aureus is the predominant
pathogen associated with infected metal implants (4). Although
at least nine new antimicrobial agents targeting S. aureus have
been approved since 2000 (5), there is concern that S. aureus
will acquire additional drug-resistance mechanisms that will
circumvent the effectiveness of antibiotics (6). Additionally,
because S. aureus infections cannot always be prevented by
prophylactic administration of commonly-used antibiotics in the
surgical setting, other preventative strategies are needed (7).
A S. aureus vaccine is one potential mechanism to boost
the immune system that could eradicate the infecting microbe.
Because many of the individuals most susceptible to
staphylococcal infections are the least competent to mount an
effective immune response, active as well as passive
immunization strategies must be explored (8-10), as well as
combinations of vaccination and antibiotic treatments (11).
Another strategy is to find infection-resistant implant
materials (12).
Our previous study in rats indicated that an inoculum of 103
colony forming units (CFU) of the S. aureusMN8 strain gave
reproducible signs of osteomyelitis when injected into rat
tibias and femurs along with implantation of a knee prosthesis,
including loosening of the implant after 2 weeks of infection
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(13). Inocula of >104 CFU induced massive osteomyelitis and
most of the prostheses were completely displaced. A bacterial
inoculum of 102 CFU led to no signs of osteomyelitis.
Deletion of the 4-gene ica-abcd operon encoding the proteins
needed for synthesis of the conserved cell surface
polysaccharide poly-N-acetyl glucosamine (PNAG) had a
minor effect on virulence in implant-related osteomyelitis.
In the present study, we report on findings in rats with
implanted knee prosthesis infected with 103 CFU of ica+ S.
aureus MN8 following active vaccination against the PNAG
antigen using a synthetic oligosaccharide-protein conjugate
vaccine under development for human use. We also evaluated
the impact of passive immunization, using antiserum obtained
from a goat injected with the same vaccine, against implant-
associated infection with both ica+ and ica− S. aureus MN8.
Materials and Methods 
Experimental design. Fifty-two male Sprague-Dawley rats, 7-9 weeks-
old (Taconic Europe) with a weight of about 300 g were used for these
experiments. Rats were divided into active (n=28 at start, two post-
surgical deaths, 26 evaluable cases) and passive immunization groups
(n=24 at start, three post-surgical deaths, 21 evaluable cases). Rats
were infected with 103 CFU of PNAG-producing (ica+) wild-type S.
aureus MN8 or an isogenic mutant with deletion of the ica genes
(ica::tet), referred to as the ica− strain. The rats received the bacterial
inoculations into the marrow of the tibia and femur before insertion of
a non-constrained knee prosthesis. Each group (n≥5) had a matched
control group (n=4-8). Animals were clinically and radiographically
followed for 2 weeks and then sacrified using an intracardiac injection
of 2 ml of 200 mg pentobarbital/ml. Histological and microbiological
analysis were then carried out.
The animal protocols were approved by the Animal Ethics
Committee of Denmark (2005/561-1049 and 2012-15-2934-00684).
All the animal studies were carried out at The Panum Institute the
University of Copenhagen, under supervision of a veterinarian. 
Immunization procedure. Actively immunized controls received
sodium chloride (NaCl) subcutaneously and passively immunized
controls received normal goat serum intraperitoneally. The active-
immunization group received cutaneous injections of a 10 μg/dose of
a synthetic PNAG oligosaccharide, 9G1cNH2, conjugated to tetanus
toxoid (9GlcNH2-TT), previously described (14), 3, 2 and 1 week
before implantation of the prostheses. The passive immunization
group received immune or normal antisera intraperitoneally on days
−3, 0, 3, 6, 9 and 12, where day 0 was the day of operation.
S. aureus strains and infection process. We used the MN8 strain of
S. aureus originally obtained from a patient with toxic shock
syndrome (15, 16). Each rat was injected with 10 μl containing 103
CFU of ica+ or ica− S. aureus strain MN8 into the medullary canals
of the femur and tibia. The suspension was injected into the marrow
hole and after that the condylar prosthesis was inserted. 
Operative procedure, materials required and anesthesia. All rats
were sedated with a subcutaneous injection of hypnorm/dormicum
0.3 ml/100 g given preoperatively and re-administered every 15
minutes at 0.15 ml/100 g. 
The skin over the left knee was sterilized twice with alcohol. The
fur was shaved with a razor. The knee was opened with a para-
patellar medial incision and the tendon with the patella was
dislocated laterally. The articulating cartilage was osteotomized with
bone scissors from the distal femur and the proximal tibia inclusive
of the menisci and cruciate ligaments protecting the collateral
ligaments. A 2 mm wide and a 10 mm deep hole was bored into the
femur and tibia with a hand drill to fit the joint components. A rat-
sized, in-house designed and produced non-constrained knee
prosthesis was used. The joint capsule and skin were closed with
Ethibond 4-0 and Vicryl 50 after placement of the knee prosthesis,
a press-fit model, without bone cement (13).
After the operation, a femoralis block of the operated extremity
was placed below the inguinal ligament using 1% lidocaine/0.5%
bupivacaine in 1 ml.
Radiographic evaluation. Front and lateral X-ray images were taken
on days 0 (operation), 7 and 14. In order to assess development and
progression of bone infection, the modified scoring system of An et
al. (17) was used. The scoring system uses radiographic evaluation
of infected bone grading the involved bone for periosteal reaction,
osteolysis, soft-tissue swelling, deformity, sequestrum formation,
spontaneous fracture and general impression. 
Clinical evaluation. Body weight, temperature and well-being of the
animal were monitored by a veterinarian. 
Microbiological evaluation. After sacrifice, the prosthesis
components were explanted and rolled over non-selective solid
media (5% Danish blood agar and chocolate agar plates; State Serum
Institute, Copenhagen, Denmark) and then cultured. Isolated bacteria
were identified as previously described (18) and the plates scored for
growth as follows: growth in the first streak: 1, growth in the first
two streaks: 2, and growth in all three streaks: 3. 
Bone and soft-tissue histology. After removal of the prosthesis, the
remnants of the tibia, femur and synovialis were fixed in 4%
buffered paraformaldehyde and decalcified in 10% formic acid for
7 days in EDTA. Samples were then embedded in paraffin, and
transverse sections of 5 μm, including the implantation site, were
cut on a microtome. The sections were stained using hematoxylin-
eosin. Semiquantitative scoring of all specimens was performed
blind by a pathologist who was not aware of the treatment groups
(SSP9). For histological scoring of severity of inflammation,
transverse sections of the tibia and femur (with the prosthesis
removed) and tissue from the synovialis were investigated. Each of
the three tissues (femur, tibia, and synovialis) was given a score
ranging from 0 to 4, depending on the severity of inflammation. 0
meant no signs of inflammation, 1 was slight focal accumulation
of inflammatory cells (neutrophils), 2 was moderate but consistent
inflammation in the transverse sections or moderate inflammation
of the entire circumference around the cavity after prosthesis
removal, 3 was the start of formation of an abscess in the cavity,
and 4 was abscess formation and destruction of bone material with
the synovialis completely infiltrated by neutrophils. The scores
from the three separate tissues were added, giving a maximum
score of 12.
Biochemical analysis. Alpha-(1)-acid glycoprotein (AGP) (normal
range=0-130 ng/ml), an acute-phase protein, was measured on days
0 (preoperative), 7 and 14 (19). 
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Data analysis. Due to the small number of animals per group, the
discrete nature and narrow range of the measurements, it was chosen
not to perform statistical analyses. 
Results
Microbiological results. In the actively-immunized group, a
decrease in bacterial numbers in the ica+ group immunized
against PNAG compared to the control was achieved as seen
from the microbiological score shown in Figure 1. In the
PNAG-immune rats challenged with the ica− strain there was
a similar decrease. Among passively immunized rats, the anti-
PNAG serum resulted in decreased bacterial levels, compared
to controls given normal goat serum, regardless of whether
they were infected with ica+ or ica− S. aureus. For mice with
antibody to PNAG, the mean microbiological score was
threefold in the ica+ group compared to the ica− group but
lower than that in the ica+ control group, although the same
as that for the ica− controls. 
Biochemistry. All data appeared to show an effect of active
immunization against the ica+ strain. In the passively
immunized group, there was an effect in groups challenged
with either the ica+ or ica− strain compared to the control
group receiving normal goat serum after 1 and 2 weeks. The
basis for the apparent specificity of protective effects
following active immunization against PNAG for the PNAG-
producing strain is clear. The apparent lack of specificity for
the effect of the anti-PNAG-immune serum on both PNAG
and non-PNAG-expressing S. aureus is less clear, it may be
that this serum has antibodies to multiple S. aureus antigens
active against both ica+ and ica− strains.
X-Ray examination. The radiological analysis showed signs
of an effect in both actively and passively immunized groups,
with a minimum factor of 2 (Figure 1). 
Histopathological findings. Infiltration by inflammatory cells
was clearly observed around the prosthesis (Figure 2A and D)
in all control groups. There was a decrease in inflammation
in both immunized groups (Figure 2B, C and E), where mean
scores were clearly lower in the ica+ actively immunized
group and in the ica− passively immunized group (Figure 1).
Clinical results. There were no apparent differences in mean
weight loss between the immunized and the control groups.
All prostheses were in situ with loosening in the control
groups. No deep wounds around the knees were seen in any
animals of any group.
Discussion
This in vivo animal study of both active and passive
immunization showed that the strongest effects on the
parameters measured were seen in rats actively immunized
with a vaccine to induce a protective antibody against PNAG
that were then challenged with an ica+ PNAG-producing
strain of S. aureus. When compared to non-immune control
groups, lower AGP levels (reflecting microbiologic burden),
x-ray scores and pathology scores were achieved by
immunizing against PNAG and challenging with a wild-type,
ica+ strain. Passive immunization had a less pronounced effect
on the ica+ strain, with a more pronounced effect on the
PNAG-negative S. aureus variant. This is most readily
explained by the presence of antibodies to multiple S. aureus
antigens in the passively administered immunoglobulin
obtained from an immunized goat. These would be expected
to be effective against ica− S. aureus. The greater effect of the
post-infection goat antiserum on the ica− strain compared to
the ica+ strain suggests that the presence of the PNAG antigen
on the bacterial surface reduces the efficacy of the antibodies
against the non-PNAG antigens on the bacterial surface.
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Figure 1. A. ica+ bacteria: The intercellular adhesion (ica) locus is
present in Staphylococcus aureus and represents biofilm formation. B.
ica– bacteria: the strains are characterized as negative for the biofilm
formation.
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Figure 2. A: Extensive inflammatory exudate in the femur cavity from an unimmunized control rat. B: Slightly less inflammation in the femur marrow
in a rat passively immunized. C: The cavity of the femur from a rat from the group actively immunized showing almost no inflammation. D: Higher
magnification of the inflammatory exudate depicted in (A), showing heavy infiltration of inflammatory cells including polymorphonuclear leucocytes
in the femur marrow. E: Higher magnification of area from (C), showing almost total absence of inflammatory reaction at the surface of the cavity
where the implant is positioned. Stain: Hematoxylin–eosin.
PNAG, also known as intercellular adhesion polysaccharide
(20), is a surface polymer produced by both S. aureus and S.
epidermis, and many other pathogens (21). PNAG promotes
biofilm formation and enhances staphylococcal virulence in
mouse infection models (12, 22). In other studies,
investigators immunized mice, rabbits and goats with either
native PNAG, containing >90% acetate substituents on the
amino groups in the glucosamine molecule, or dPNAG,
wherein the acetate substitution is <20%, conjugated to
diphtheria toxoid (20). This study and another (22) indicated
that antibodies to dPNAG, but not native PNAG, are opsonic
and provide protection against experimental S. aureus
infection. Additional studies using synthetic oligosaccharides
of PNAG and dPNAG conjugated to carrier proteins
confirmed the need to use only non-acetylated glucosamines
for vaccination to achieve protective immunity (14, 21), most
likely via opsonic killing of bacteria. Thus, numerous
investigations have consistently found an effect on infection
and disease when opsonic antibody to PNAG is present due
to either active or passive immunization (23-25).
In our study, we saw significant protection against the
PNAG+ strain for the actively immunized group, with scores
of 2-3, representing minimal infection and pathology, for all
parameters. With the PNAG− strain, we saw a reduction in
measured parameters compared to controls but not to the
same degree as seen with the PNAG+ strain. It is not
surprising that a vaccine targeting the PNAG antigen is much
less effective when the ica− gene is missing. This diminished
effect is indicative of the specificity of the protection induced
by vaccination.
Other preclinical animal studies revealed that mice
immunized with a recombinant form of an adhesin, which
mediates S. aureus binding to fibrinogen and promotes the
attachment to biomaterial surfaces (26), reduced arthritis and
lethality induced by S. aureus. However, protection was strain-
dependent (27). Another study described a monoclonal
antibody for inhibiting the effects of the accessory gene
regulator (agr) of virulence in S. aureus (28). The monoclonal
antibody reduced the expression of the effector molecule of
the agr system, AgrC, and protected against infection. Another
group showed that a monoclonal antibody to S. aureus
glucosaminidase protects against implant-associated infections
(25). In our study, we saw a significant effect on the various
parameters in the rats passively immunized with antibody to
PNAG and challenged with the ica− S. aureus strain when
compared to the control group. The effect on the ica− strain is
somewhat difficult to evaluate as only four control animals
given normal goat serum were available for analysis.
The animal model is suitable for reliably inducing implant
osteomyelitis. Active immunization was shown to markedly
reduce the consequences of infection from ica+ S. aureus-
induced osteomyelitis. Passive immunization with a mixture
of antibodies to multiple S. aureus antigens gave a notable
effect in both the ica+ and ica− groups and it seems that the
effects observed might be statistically significant if more
animals were included in the study. Choosing appropriate
antigens to include in an immunization strategy is a major
challenge in creating a staphylococcal vaccine. Immunization
based on only a single virulence determinant could have
limited efficacy because of the multifactorial nature of the
pathogenesis of staphylococcal infection. A number of S.
aureus vaccines composed of inactive toxins or their subunits
have been evaluated pre-clinically (29). The value of adding
toxin components to multicomponent prophylactic vaccine
formulation is unresolved. Overall, an effective vaccine for
S. aureus-induced osteomyelitis should include candidate
antigens that are surface exposed and expressed by most of
the clinical S. aureus strains. 
In developing vaccines against S. aureus, both active and
passive immunization approaches should be pursued, as these
are not mutually exclusive and may well turn out to be
complementary.
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